Navigation Links
YM BIOSCIENCES REPORTS 2007 YEAR END OPERATIONAL AND FINANCIAL RESULTS
Date:9/23/2007

MISSISSAUGA, ON, Sept. 24 /PRNewswire-FirstCall/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today reported operational and financial results for the fourth quarter and the 2007 fiscal year, ended June 30, 2007.

"YM's business model, which unremittingly has been to diversify against the risk of clinical failure, has made it possible for us to mitigate in part just such an unfortunate event earlier this year with the disappointing results of the tesmilifene trial. With recruitment in nimotuzumab's first Phase III trial having been completed; the initiation of two additional late stage trials this current quarter; with substantial international financial and human resources supporting a broad and aggressive development program for nimotuzumab; with AeroLEF(TM) having successfully completed its first randomized trial and being prepared for its Phase III trials, we have seen the benefits of adhering to our corporate strategy. This strategy permits us to continue to take our late-stage products forward to surface their value," said David Allan, Chairman and CEO of YM BioSciences. "Importantly, we start the current fiscal year with more than US$65 million of cash available to support our development programs."

Nimotuzumab:

Nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR), is currently in varying stages of development in a number of trials, including colorectal cancer, adult and pediatric glioma, non-small-cell lung cancer and pancreatic cancer. YM expects that the range of indications will continue to broaden in 2008 as the group's coop
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Perscitus Biosciences secures $250K Commerce loan
2. Wisconsin biosciences rise to the challenge
3. Quintessence Biosciences advances cancer drug
4. Quintessence Biosciences names new president
5. Caden Biosciences may signal critical mass
6. Wisconsin start up Primorigen Biosciences corrals out-of-state investment
7. WARF signs licensing pact with BD Biosciences
8. Fisher Biosciences contracts with Madison-based GenTel BioSurfaces
9. State awards QRG Biosciences development grant
10. EMD Biosciences partners with European biotech company
11. Quintessence Biosciences forms cancer therapeutic advisory board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 “Preparative & Process ... Flash), Consumables (Columns, Solvents, Buffers, Valves, Guages, Seals), ... Agriculture) - Forecasts to 2019” provides a detailed ... current market trends, and strategies impacting the preparative ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
(Date:12/24/2014)... December 23, 2014 On Friday, December ... the Omnibus and Continuing Resolution Appropriations Act of 2015, ... eligible to receive funding through the Congressionally Directed Medical ... (DoD). The Hydrocephalus Association (HA), working in conjunction with ...
(Date:12/24/2014)... Dallas, Texas (PRWEB) December 23, 2014 ... mercaptan such as its definition, classification, application and ... manufacturing process, and product cost structure. Production is ... also covers upstream raw materials, equipment, downstream client ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... LASIK Surgeons directory service and information resource for ... Trusted LASIK Surgeons directory apart is a unique ... surgeon who are among the best in the ... LASIK Surgeon Dr. Parag A. Majmudar, are screened ...
... line in the United ... States and Canada, ... into a partnership that will allow Roche to market,the first line ... the RAMP(R) 200 (Rapid Analyte Measurement Platform), is,based on RAMP technology ...
... Medical,Technologies, Inc. (Nasdaq: VNUS ), a leading provider ... reflux disease, today,announced its plans to present at the ... held August 5-6, 2008, at the Millennium,Broadway Hotel in ... for 10:00 a.m. ET on,Wednesday, August 6, and will ...
Cached Biology Technology:Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 2Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 3Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 4Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 5Chicago LASIK Specialist Parag A. Majmudar, M.D. Joins LASIK and Refractive Surgeons Directory at Trusted LASIK Surgeons 6Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 2Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests 3
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ) has ... - Home Button Synaptics Fingerprint Sensor Technology Analysis" ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a totally different ... the first time a fingerprint sensor in its product. ...
(Date:12/17/2014)... 16, 2014 Valencell, a leader in performance biometric ... to industry leaders such as Intel, Jabra, Atlas, and ... wearable products. These products will be showcased at CES ... Vegas . "Our partners choose ...
(Date:12/15/2014)... Dec. 12, 2014 Research and Markets ( ... "Global Facial Recognition Market 2015-2019" report to their ... Facial recognition is a technology used for the ... facial feature of a person such as nose, jaw ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Northwest is the focus of two federal grants totaling ... They will work together on a pair of multi-site ... and property from wildfires in the face of a ... the UO,s Center for Ecology and Evolutionary Biology, will ...
... of the element boron in a new generation of drugs ... Boron has to date far been one of biology,s best ... and investment from the pharmaceutical industry in the quest for ... limitations and side effects of current products. Europe,s ...
... Conventional wisdom has been that respiratory syncytial virus (RSV) ... comes and goes in children without any long lasting impact. ... Southwestern Medical Center researchers, however, suggests that RSV may hide ... to cause recurrent wheezing and chronic airway disease. ...
Cached Biology News:Northwest climate change is target of $3.2M in grants to University of Oregon 2Northwest climate change is target of $3.2M in grants to University of Oregon 3Northwest climate change is target of $3.2M in grants to University of Oregon 4European researchers harness unique properties of boron to develop new drugs and diagnostics 2European researchers harness unique properties of boron to develop new drugs and diagnostics 3RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report 2RSV may hide in the lungs, lead to asthma, UT Southwestern researchers report 3
PxE thermal Cycler. 0.5ml block holds 48 0.5 ml tubes or 96 0.3 ml tubes. Adjustable height heated lid. Outstanding uniformity. Advanced control algorithms for reduced reaction times. User frien...
Carrier Serum...
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
... Taq is a derivative of Taq DNA ... Thermus aquaticus DNA polymerase. Expressed from a ... at Met236, bypassing the 5'-3' exonuclease domain ... reveals a highly active and even more ...
Biology Products: